The use of serum hCG as a marker of tumor progression and of the response of metastatic urothelial cancer to systemic chemotherapy

This case confirms the observation that urothelial carcinomas can secrete beta-hCG, and that beta-hCG can potentially be used as a marker of a patient's clinical response to treatment. Prospective studies are clearly warranted by these observations.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncology (Williston Park, N.Y.) N.Y.), 2013-10, Vol.27 (10), p.1028, 1030-1030
Hauptverfasser:	Malkhasyan, Karen, Deshpande, Hari A, Adeniran, Adebowale J, Colberg, John W, Petrylak, Daniel P
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers, Tumor - blood Cancer Chemotherapy Chorionic Gonadotropin, beta Subunit, Human - blood Development and progression Disease Progression Drug therapy Female Gonadotropin Health aspects Humans Middle Aged Neoplasm Metastasis Physiological aspects Urinary Bladder Neoplasms - blood Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - pathology Urinary tract cancer
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This case confirms the observation that urothelial carcinomas can secrete beta-hCG, and that beta-hCG can potentially be used as a marker of a patient's clinical response to treatment. Prospective studies are clearly warranted by these observations.
ISSN:	0890-9091